Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.91 USD

102.91
1,582,242

-0.30 (-0.29%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $102.90 -0.01 (-0.01%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes

by Zacks Equity Research

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Bruker (BRKR) Introduces Magnet Technology for NMR Adoption

by Zacks Equity Research

Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.

Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers

by Zacks Equity Research

Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.

Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JPME

Here's Why Cardinal Health (CAH) Fell More Than Broader Market

by Zacks Equity Research

Cardinal Health (CAH) concluded the recent trading session at $109.47, signifying a -0.41% move from its prior day's close.

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Philips (PHG) Boosts Patient Monitoring With smartQare Deal

by Zacks Equity Research

Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.

BD's (BDX) Latest Product to Offer Wider Access to Researchers

by Zacks Equity Research

The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

by Zacks Equity Research

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Abbott (ABT) Faces Low Testing Demand, Currency Headwinds

by Zacks Equity Research

Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.

IM Cannabis (IMCC) Expands Business in Germany With New Alliance

by Zacks Equity Research

The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.

Should Value Investors Buy Cardinal Health (CAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

Labcorp (LH) Extends MRD Clinical Research With New Launch

by Zacks Equity Research

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

by Zacks Equity Research

Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

by Zacks Equity Research

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Abbott (ABT) Receives FDA's Approval for the TriClip TEER System

by Zacks Equity Research

Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

by Zacks Equity Research

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

by Zacks Equity Research

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

by Zacks Equity Research

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

Why Cardinal (CAH) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care

by Zacks Equity Research

GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.

Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS

by Zacks Equity Research

Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.